Brodalumab: Six-Year US Pharmacovigilance Report

By sjmartinez • November 27, 2024

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL Jr, Mangin GD, Jacobson AA. Brodalumab: Six-Year US Pharmacovigilance Report. Dermatol Ther (Heidelb). 2024 Nov 26. doi: 10.1007/s13555-024-01304-y. Epub ahead of print. PMID: 39589679.

Tags: Adverse events, Dermatology, Drug reaction, psoriasis, Publications, real-world, safety

Letter to the Editor: Comment on Bocanegra-Oyola et al’s “Clinical Characteristics of Ocular Mucous Membrane Pemphigoid: A Systematic Review and Meta-Analysis”

Kasperkiewicz M. Letter to the Editor: Comment on Bocanegra-Oyola et al's "Clinical Characteristics of Ocular Mucous Membrane Pemphigoid: A Systematic Review and Meta-Analysis". Ocul Immunol[...]

Response to Baroukhian et al., “Pemphigus following herpes simplex infection: A global comprehensive cohort study”

Curman P, Ngo BT, Hernandez G, Kridin K, Ludwig RJ, Kasperkiewicz M. Response to Baroukhian et al., "Pemphigus following herpes simplex infection: A global comprehensive[...]

Inhibition of pyruvate oxidation diminishes melanoma progression

Seyran B, Avila I, Galvan C, Robles G, Murphy C, Christofk H, Lowry WE. Inhibition of pyruvate oxidation diminishes melanoma progression. J Invest Dermatol. 2024[...]